Business
CDT Announces Canadian Patent for AZD5904 in Male Infertility
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key pharmaceutical target markets. CDT believes that the extensive geographical coverage of this patent combined with its more recent composition of matter application provides a strong IP position for develop
About this update from Cdt Equity Inc.
[{"type":"text","content":"NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key pharmaceutical target markets.","length":325,"tagName":"p"},{"type":"text","content":"CDT believes that the extensive geographical coverage of this patent combined with its more recent composition of matter application provides a strong IP position for development of AZD5904 in male infertility as discussions continue regarding potential licensing and strategic partnering opportunities.","length":303,"tagName":"p"},{"type":"text","content":"Originally licensed from AstraZeneca, AZD5904 benefits from an extensive clinical safety package alongside pre-clinical validation in an area of significant unmet medical need and a continually growing market.","length":209,"tagName":"p"},{"type":"text","content":"“Globally, the male infertility market is estimated at approximately USD $4.4 billion annually, representing a significant area of unmet medical need with no approved drug therapies specifically addressing male infertility,” said Dr. Joanne Holland, Chief Scientific Officer of CDT. “The Canadian approval further strengthens the global positioning of AZD5904 as we continue advancing partnering and future development discussions.”","length":432,"tagName":"p"},{"type":"text","content":"About CDT Equity Inc. ","length":21,"tagName":"p"},{"type":"text","content":"CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.","length":657,"tagName":"p"},{"type":"text","content":"Cautionary Statement Regarding Forward-Looking Statements ","length":57,"tagName":"p"},...